Improved murine MHC-deficient HLA transgenic NOD mouse models for type 1 diabetes therapy development

Jeremy J. Racine, Isabel Stewart, Jeremy Ratiu, Greg Christianson, Emily Lowell, Kelsay Helm, Jennifer Allocco, Richard S. Maser, Yi Guang Chen, Cathleen M. Lutz, Derry Roopenian, Jennifer Schloss, Teresa P. DiLorenzo, David V. Serreze

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Improved mouse models for type 1 diabetes (T1D) therapy development are needed. T1D susceptibility is restored to normally resistant NOD.β2m-/- mice transgenically expressing human disease-associated HLA-A02:01 or HLA-B39:06 class I molecules in place of their murine counterparts. T1D is dependent on pathogenic CD8+ T-cell responses mediated by these human class I variants. NOD.β2m-/--A2.1 mice were previously used to identify β-cell autoantigens presented by this human class I variant to pathogenic CD8+ T cells and for testing therapies to attenuate such effectors. However, NOD.β2m-/- mice also lack nonclassical MHC I family members, including FcRn, required for antigen presentation, and maintenance of serum IgG and albumin, precluding therapies dependent on these molecules. Hence, we used CRISPR/Cas9 to directly ablate the NOD H2-Kd and H2-Db classical class I variants either individually or in tandem (cMHCI-/-). Ablation of the H2-Ag7 class II variant in the latter stock created NOD mice totally lacking in classical murine MHC expression (cMHCI/II-/-). NOD-cMHCI-/- mice retained nonclassical MHC I molecule expression and FcRn activity. Transgenic expression of HLA-A2 or-B39 restored pathogenic CD8+ T-cell development and T1D susceptibility to NOD-cMHCI-/- mice. These next-generation HLA-humanized NOD models may provide improved platforms for T1D therapy development.

Original languageEnglish (US)
Pages (from-to)923-935
Number of pages13
JournalDiabetes
Volume67
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Inbred NOD Mouse
Type 1 Diabetes Mellitus
Transgenic Mice
T-Lymphocytes
HLA-B39 Antigen
Clustered Regularly Interspaced Short Palindromic Repeats
HLA-A2 Antigen
Therapeutics
Autoantigens
Antigen Presentation
Cell- and Tissue-Based Therapy
varespladib methyl
Serum Albumin
Immunoglobulin G
Maintenance

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Racine, J. J., Stewart, I., Ratiu, J., Christianson, G., Lowell, E., Helm, K., ... Serreze, D. V. (2018). Improved murine MHC-deficient HLA transgenic NOD mouse models for type 1 diabetes therapy development. Diabetes, 67(5), 923-935. https://doi.org/10.2337/db17-1467

Improved murine MHC-deficient HLA transgenic NOD mouse models for type 1 diabetes therapy development. / Racine, Jeremy J.; Stewart, Isabel; Ratiu, Jeremy; Christianson, Greg; Lowell, Emily; Helm, Kelsay; Allocco, Jennifer; Maser, Richard S.; Chen, Yi Guang; Lutz, Cathleen M.; Roopenian, Derry; Schloss, Jennifer; DiLorenzo, Teresa P.; Serreze, David V.

In: Diabetes, Vol. 67, No. 5, 01.05.2018, p. 923-935.

Research output: Contribution to journalArticle

Racine, JJ, Stewart, I, Ratiu, J, Christianson, G, Lowell, E, Helm, K, Allocco, J, Maser, RS, Chen, YG, Lutz, CM, Roopenian, D, Schloss, J, DiLorenzo, TP & Serreze, DV 2018, 'Improved murine MHC-deficient HLA transgenic NOD mouse models for type 1 diabetes therapy development', Diabetes, vol. 67, no. 5, pp. 923-935. https://doi.org/10.2337/db17-1467
Racine JJ, Stewart I, Ratiu J, Christianson G, Lowell E, Helm K et al. Improved murine MHC-deficient HLA transgenic NOD mouse models for type 1 diabetes therapy development. Diabetes. 2018 May 1;67(5):923-935. https://doi.org/10.2337/db17-1467
Racine, Jeremy J. ; Stewart, Isabel ; Ratiu, Jeremy ; Christianson, Greg ; Lowell, Emily ; Helm, Kelsay ; Allocco, Jennifer ; Maser, Richard S. ; Chen, Yi Guang ; Lutz, Cathleen M. ; Roopenian, Derry ; Schloss, Jennifer ; DiLorenzo, Teresa P. ; Serreze, David V. / Improved murine MHC-deficient HLA transgenic NOD mouse models for type 1 diabetes therapy development. In: Diabetes. 2018 ; Vol. 67, No. 5. pp. 923-935.
@article{558baeaaac7a4fcea7e993cf7bc8b5b9,
title = "Improved murine MHC-deficient HLA transgenic NOD mouse models for type 1 diabetes therapy development",
abstract = "Improved mouse models for type 1 diabetes (T1D) therapy development are needed. T1D susceptibility is restored to normally resistant NOD.β2m-/- mice transgenically expressing human disease-associated HLA-A∗02:01 or HLA-B∗39:06 class I molecules in place of their murine counterparts. T1D is dependent on pathogenic CD8+ T-cell responses mediated by these human class I variants. NOD.β2m-/--A2.1 mice were previously used to identify β-cell autoantigens presented by this human class I variant to pathogenic CD8+ T cells and for testing therapies to attenuate such effectors. However, NOD.β2m-/- mice also lack nonclassical MHC I family members, including FcRn, required for antigen presentation, and maintenance of serum IgG and albumin, precluding therapies dependent on these molecules. Hence, we used CRISPR/Cas9 to directly ablate the NOD H2-Kd and H2-Db classical class I variants either individually or in tandem (cMHCI-/-). Ablation of the H2-Ag7 class II variant in the latter stock created NOD mice totally lacking in classical murine MHC expression (cMHCI/II-/-). NOD-cMHCI-/- mice retained nonclassical MHC I molecule expression and FcRn activity. Transgenic expression of HLA-A2 or-B39 restored pathogenic CD8+ T-cell development and T1D susceptibility to NOD-cMHCI-/- mice. These next-generation HLA-humanized NOD models may provide improved platforms for T1D therapy development.",
author = "Racine, {Jeremy J.} and Isabel Stewart and Jeremy Ratiu and Greg Christianson and Emily Lowell and Kelsay Helm and Jennifer Allocco and Maser, {Richard S.} and Chen, {Yi Guang} and Lutz, {Cathleen M.} and Derry Roopenian and Jennifer Schloss and DiLorenzo, {Teresa P.} and Serreze, {David V.}",
year = "2018",
month = "5",
day = "1",
doi = "10.2337/db17-1467",
language = "English (US)",
volume = "67",
pages = "923--935",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "5",

}

TY - JOUR

T1 - Improved murine MHC-deficient HLA transgenic NOD mouse models for type 1 diabetes therapy development

AU - Racine, Jeremy J.

AU - Stewart, Isabel

AU - Ratiu, Jeremy

AU - Christianson, Greg

AU - Lowell, Emily

AU - Helm, Kelsay

AU - Allocco, Jennifer

AU - Maser, Richard S.

AU - Chen, Yi Guang

AU - Lutz, Cathleen M.

AU - Roopenian, Derry

AU - Schloss, Jennifer

AU - DiLorenzo, Teresa P.

AU - Serreze, David V.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Improved mouse models for type 1 diabetes (T1D) therapy development are needed. T1D susceptibility is restored to normally resistant NOD.β2m-/- mice transgenically expressing human disease-associated HLA-A∗02:01 or HLA-B∗39:06 class I molecules in place of their murine counterparts. T1D is dependent on pathogenic CD8+ T-cell responses mediated by these human class I variants. NOD.β2m-/--A2.1 mice were previously used to identify β-cell autoantigens presented by this human class I variant to pathogenic CD8+ T cells and for testing therapies to attenuate such effectors. However, NOD.β2m-/- mice also lack nonclassical MHC I family members, including FcRn, required for antigen presentation, and maintenance of serum IgG and albumin, precluding therapies dependent on these molecules. Hence, we used CRISPR/Cas9 to directly ablate the NOD H2-Kd and H2-Db classical class I variants either individually or in tandem (cMHCI-/-). Ablation of the H2-Ag7 class II variant in the latter stock created NOD mice totally lacking in classical murine MHC expression (cMHCI/II-/-). NOD-cMHCI-/- mice retained nonclassical MHC I molecule expression and FcRn activity. Transgenic expression of HLA-A2 or-B39 restored pathogenic CD8+ T-cell development and T1D susceptibility to NOD-cMHCI-/- mice. These next-generation HLA-humanized NOD models may provide improved platforms for T1D therapy development.

AB - Improved mouse models for type 1 diabetes (T1D) therapy development are needed. T1D susceptibility is restored to normally resistant NOD.β2m-/- mice transgenically expressing human disease-associated HLA-A∗02:01 or HLA-B∗39:06 class I molecules in place of their murine counterparts. T1D is dependent on pathogenic CD8+ T-cell responses mediated by these human class I variants. NOD.β2m-/--A2.1 mice were previously used to identify β-cell autoantigens presented by this human class I variant to pathogenic CD8+ T cells and for testing therapies to attenuate such effectors. However, NOD.β2m-/- mice also lack nonclassical MHC I family members, including FcRn, required for antigen presentation, and maintenance of serum IgG and albumin, precluding therapies dependent on these molecules. Hence, we used CRISPR/Cas9 to directly ablate the NOD H2-Kd and H2-Db classical class I variants either individually or in tandem (cMHCI-/-). Ablation of the H2-Ag7 class II variant in the latter stock created NOD mice totally lacking in classical murine MHC expression (cMHCI/II-/-). NOD-cMHCI-/- mice retained nonclassical MHC I molecule expression and FcRn activity. Transgenic expression of HLA-A2 or-B39 restored pathogenic CD8+ T-cell development and T1D susceptibility to NOD-cMHCI-/- mice. These next-generation HLA-humanized NOD models may provide improved platforms for T1D therapy development.

UR - http://www.scopus.com/inward/record.url?scp=85046031203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046031203&partnerID=8YFLogxK

U2 - 10.2337/db17-1467

DO - 10.2337/db17-1467

M3 - Article

C2 - 29472249

AN - SCOPUS:85046031203

VL - 67

SP - 923

EP - 935

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 5

ER -